secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-01-24T23:59:59+00:00
Accession:  0001193125-23-013704
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA
---------------------------------------------------------------

- Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.
- VP-102 is intended for the treatment of molluscum contagiosum.
- No additional details regarding the resubmission content or timeline were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/0001193125-23-013704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/d429269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-013704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer